Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00p -1.43% 69.00p 68.00p 70.00p 70.00p 69.00p 70.00p 19,606 14:03:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.4 -5.4 -8.6 - 51.62

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
20/10/201615:03ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET3,685
08/10/201612:43Angle PLC 201130,115
02/12/201513:04Angle 2016 – Liquid Biopsy Takeover Target-
23/9/201411:32Angle (35p) Broker value 126p (26/2/10)3,885

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 70p.
Angle Plc has a 4 week average price of 70.13p and a 12 week average price of 65.89p.
The 1 year high share price is 81.50p while the 1 year low share price is currently 53p.
There are currently 74,815,774 shares in issue and the average daily traded volume is 29,884 shares. The market capitalisation of Angle Plc is £51,622,884.06.
miavoce: 2 x 100k late buys just reported. If EFH is buying up stock to return to AN (most likely cause of the buying IMO) then this is good news not just for the short term price, but also for the longer term. The shares being bought are coming from weak holders, and will be going into the ownership of a very strong holder (AN), and so the shares are effectively disappearing from the market. The removal of 1.35m shares from the market, and in particular from the hands of weak holders, can only be a good thing for the share price as it tightens the available supply in future. Giving the timing of this spate of buying (i.e. just a few weeks before the EFH contract expires) it feels like too much of a coincidence for it not to be EFH. However, if it isn't then somebody else seems to be building a large stake - hopefully not a prelude to a low ball bid from a predator.
longshanks: It is difficult to assess quite how EFH have used their "temporary" holdings in AGL. The likelihood is that they have worked the holdings in a number of ways - but given the share price trend of the last two years it is likely they have "encouraged" selling and are currently short of the original holding. My guess is that they have been both buying and selling throughout - acting almost as a market maker role. Whilst probably still short of stock, I doubt it is more than 200,000 shares.
miavoce: Price falls a few pence and out come the doom mongers - even more predictable than the AGL price !!
fraybentos2: a review of my 2016 predictions large dilution Q2 with placing | proven correct no general fda approval for harvesting | proven correct ovarian trial will drift into 2017 | angle now hedging their bets Whilst the timing is dependent on a number of factors including the speed of patient recruitment and enrolment blah blah no corporate deal without ovarian results | still correct no data for other indications will rerate shares | proven correct share price will drift and will be driven below 42p when newland gifts more shares to efh | no news expected now and all firepower used just wait for the price to start drifting down this ignores wider stock market troubles happy new year sheeple target share price below 42p you have been warned
escapetohome: Only a month ago following mr an's ramp ' dont be out of the shares' the share price went to 80p. A good price for a fund raising? Perhaps the instis thought such a price 80p far too high. The share price then falls to 64p , allowing the no discount satisfaction------ apparently so. Im hanging on to my remaining shares
banshee: Indeed, I think AN now expects the AGL Share Price to undergo the financial equivalent of a multiple orgasm in the next few months, if that presentation was anything to go by. He might as well have been holding a sign up saying "This is going to multibag" during his talk.
willfy: Maybe because there is finally a trade on there, 100 buy AGL share price as slumped, but the American share price as not moved, so probably in line with our share price
chris1604: Good Morning All The descent into the 50`s has prompted me to have a look at the recent musings on the BB. Things do not appear to be changing too much, although I do sense a slight increase in the sense of unease at Newland`s performance. The BB remains one of the best on ADVFN with posters showing remarkable resilience in the face of the inexorable decline in the shareprice. So,where do we go from here. IMHO there is no short term driver for the share price and the share price will continue to suffer from the shambles surrounding the FDA approval process.I think a further fund raising exercise will be necessary to compensate for the lack of revenue.PI`s are underwater from the last fund raising and any future exercise would have to be carried out circa 40p mark. The KOL updates do not have much impact on the share price and the lack of interest shown by big pharma must concern holders here I will have another look here,if,or should I say when,the share price enters the 40`s. In the meantime I have added to my holding in VEC,as this is less of a punt than AGL. GLA
stantonian: For info, a name check in share tips for 2016 on II. Hope everyone has a happy new year and here's looking forward to a prosperous new year for Angle!"AIM share tips for 2016 on Interactive InvestorsThursday, 31 December 2015 It will be difficult to live up to the performance of last year's AIM tips of the year, which generated an average gain of 84%. This year there is a spread of companies in the pharma, technology, media, packaging and oil services sectors. Three of the five companies offer attractive yields.Angle - 69.5pIt takes years to develop and commercialise medical devices, but LSE:AGL:Angle has reached a point with its Parsortix circulating cancer tumour cells capture technology where it has started to generate revenues from initial sales to research organisations. The test data coming out of universities and hospitals is positive, with Parsortix more reliable, in terms of capturing tumour cells and not giving false positive readings, as well as easier to use, than its competitors. The Cancer Research UK study using Parsortix for lung cancer found that it was able to capture cells that would not be detected by rivals. A clinical trial evaluating the use of Parsortix in detecting ovarian cancer is planned.The device uses a disposable cassette to capture and remove tumour cells, which are larger than healthy cells, from a patient's blood. The cells can be used for a liquid biopsy rather than having to carry out a normal biopsy to assess the patient. The system is available in the US for research, but it is still in the process of gaining US FDA (Food and Drug Administration) approval for clinical purposes.Revenues will be modest in the year to April 2016, but next year they could be more than £2 million. The research market is worth £250 million a year, with the long-term possibility of Parsortix continuing to be used by a commercial treatment as a companion diagnostic. Angle will still be burning cash, but these revenues will help to cover some of the outflow.Angle has just received the final £700,000 for the previous sale of its stake in software company Geomerics. This will supplement the cash that is already in the bank and there should be nearly £4 million left at the end of April. Angle is well-financed so that it can make continued progress with commercialising the Parsortix technology, although it will probably need to raise further cash in the longer-term. Angle has just moved to the biotech sub-sector of the healthcare sector which could help to focus interest on the company.Getech - 29pThe slump in the oil price provides an opportunity to take a look at the value available in oil-related businesses. Geological information provider LSE:GTC:Getech has warned that this year will be tough and house broker WH Ireland slashed its 2015-16 profit forecast from £2.7 million to £700,000 - down from £2 million last year - even though revenues are still expected to rise due to the April 2015 acquisition of seismic consultancy ERCL. A lack of exploration expenditure by oil and gas companies will hit demand for information.Management has gone through a number of ups and downs in the oil sector and it can ride this one out. Last year's figures were boosted by a $5 million Sonangol contract so it was always going to be difficult to reach that level again this year, but the continued weakness of the oil price is likely to hamper oil exploration activity for some time. There are opportunities to take advantage of oil companies cutting direct costs by offering outsourced services.The current valuation is partly underpinned by net cash of £3.6 million - 11p a share. The dividend is expected to be held unchanged at 2.2p a share even though it would not be covered by the current earnings forecast of 1.7p a share. The yield is 7.6%. The high operational gearing of the business means that any upturn in revenues should lead to a significant rise in the profit contribution to Getech. It is difficult to assess timing, but prospects could be much better in one year's time.Amino Technologies - 109pIPTV set top box technology developer LSE:AMO:Amino Technologies was hit by a profit warning in October. The core Amino business was knocked by contract delays and customer consolidation. Recent acquisitions Entone and Booxmedia are trading strongly and have widened the product range and customer base. The Entone boss has taken over as head of sales for the whole group and dedicated regional sales teams set up.Major shareholders have been taking advantage of the slump in the share price to add to their stakes following the profit warning. Kestrel Partners has increased its stake to 15.1%, Schroders raised its stake to 12.2%, LSE:INVP:Investec has increased its shareholding to 5.38%, while Downing has taken its stake above 3%. LSE:MGR:Miton trimmed its stake.Underlying profit for the year to November 2015 will be flat at £4.3 million and then it is forecast to jump to £8.3 million, with full contributions from Entone and Booxmedia. The shares are trading on 12 times prospective 2015-16 earnings. The business is cash generative and net cash is £2.1 million. Management has reiterated that it can continue to increase its dividend by 10% a year. That means 5.5p a share is expected for the year just ended and then 6.1p a share this year. The shares are yielding 5% on this year's expected dividend. The modest rating and high yield mean that Amino is an attractive recovery play.Coral Products - 20pInjection moulded packaging manufacturer LSE:CRU:Coral Products used to be focused on supplying DVD and CD cases. That market has slumped and Coral has replaced the business by expanding in other sectors, including food and online retail - Coral supplies delivery crates. Non-media sales are more than 85% of the total revenues, whereas four years ago they were one-fifth. Recycling product sales have been weak, but there are signs that demand is picking up.The business is cash generative and net debt has been reduced to £2.8 million at the end of October 2015, even after acquiring the food-focused Nieman Packaging. There is spare capacity at the Haydock factory so minimal capital expenditure is required. Further add-on acquisitions are likely, though. LSE:SDV:Small Companies Dividend Trust and Miton have both been willing backers for deals, so getting the funding for deals should not be a problem.House broker Daniel Stewart forecasts an improvement in profit from £1.165 million to £1.6 million in the year to April 2016 - the interims show that Coral is nearly 50% of the way towards this profit and there will be a profitable contribution from the Nieman acquisition in the second half. That means the shares are trading on less than nine times prospective earnings - based on a 10% tax charge. The forecast yield of 5% on a dividend of 1p a share is an added attraction. Coral offers organic and acquisitive growth from being a consolidator in the sector.Ten Alps - 2.38pTV programme producer, publisher and digital communications services provider LSE:TAL:Ten Alps has a good business, but it has been hampered by a weak balance sheet. That has changed following the refinancing during the summer, which also included the acquisition of TV documentaries producer Reef TV. Ten Alps has pro forma net cash and is in a strong position to grow. Serial entrepreneur Luke Johnson, who has an 11.9% stake, joined the board at the time of the refinancing.Ten Alps has got this far because it had the backing of LSE:HRI:Herald Investment Trust, which has consistently provided loans and acquired shares as Ten Alps tried to sort it out. Herald has 34.5% of the company and LSE:ATS:Artemis Alpha Trust has 15.6%. These shareholders will also back Ten Alps in its expansion plans.Management is seeking to grow the television programme production business organically and through acquisitions. Elsewhere, the strategy is to focus on its most profitable market sectors and expand the digital content and events operations through acquisition.N+1 Singer forecasts a 2015-16 profit of £1.12 million, rising to £1.83 million the following year. The shares, which have drifted back after a 10-for-one share consolidation, are trading on less than six times prospective 2016-17 earnings. Hopefully, the broker and Ten Alps have been sensible enough to set a realistic and achievable target. The market is obviously unsure at the moment and this provides a buying opportunity." *Share prices as at close of business on 22 December 2015This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
miavoce: Slippery, thanks for clarifying your views - good to see that you have no specific views about Parsortix per se. Regarding the commercialisation, the management team certainly failed initially to understand how this could be achieved and how long it would take - nobody could disagree with this. In 2013 they were talking about releasing Parsortix for sales into the research market, but at that point in time as there was little real experience of the technology in action and only limited validation of its effectiveness, thoughts of commercialisation were very premature. Looking back however, I believe the management quickly realised that there would be no commercial uptake of the technology without real life experience, industry awareness and robust validation, and hence they embarked on partnering with the leading KOL's worldwide as a means to achieve the needed validation and industry awareness of Parsortix's capability. It should be noted that these KOL's would not have come onboard if the technology did not appear to be potentially valuable in cancer diagnostics and treatment. Now that the required validation and awareness are in place, the management are being much more specific about the timelines for sales into the research / trials market i.e by end of the year. They have stated that the use of Parsortix is being planned into one or more forthcoming clinical trials. It is the timing of these trials / projects which is now driving the sales timeline. This timing is somewhat out of Angle's control, and hence there has been some movement in the sales timeframe. We appear to be within a very few months of maiden sales which, in the long timeline from concept to large scale commercialisation, means we are now in touching distance of a critical landmark event which (hopefully) will have a very positive impact on the share price My puzzlement with your decision to short AGL stems from the above. Angle is nearing an inflexion point in its development - i.e. the transition from development to commercialisation. In addition to this there should be other news flow from KOLs, collaborators and regulators which will have a positive share price impact. To me you seem to be taking an increasing risk the longer you keep your short open as meaningful news could come at any time. Clearly at the moment you can point to the fall in the share price over the recent weeks as justification for your views. However IMHO this drift downwards is driven by the poor state of the overall market and by the lack of news flow over the summer doldrums period, rather than being driven by the actual prospects for company which appear very strong. Angle's share price is currently largely driven by newsflow, and in the absence of news flow it drifts down, as we have seen time and time again over the years (which has presented a number of good buying opportunities). Regards. PS. You might want to consider going long....
Angle share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161020 19:35:33